Avanzanite Announces Exclusive Licence Agreement to Commercialise Zemcelpro® in Europe

Contributed by: Business Wire

Logo

Images

Adam Plich, Co-founder and CEO, Avanzanite Bioscience

Business Wire embedded0

Tags

Oncology

Health

Stem Cells

General Health

Pharmaceutical

Biotechnology

Zemcelpro European licencing

More Like This

PR Newswire associated0

Zemcelpro® (UM171 Cell Therapy) licensing and supply agreements announced for Europe

PR Newswire associated0

Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells

PR Newswire associated0

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

Zemcelpro® (UM171 Cell Therapy) licensing and supply agreements announced for Canada

PR Newswire associated0

Zemcelpro® distribution agreement announced for Argentina, Hong Kong and Singapore

PR Newswire associated0

Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany

PR Newswire associated0

Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting

Business Wire associated0

Avanzanite Bioscience Expands Partnership With Advicenne in Additional European Countries